ESR1 and breast carcinoma: To test if such synergy exists in the context of ESR1 mutant breast cancer, we tested OTX015 in combination with abemaciclib, an approved CDK4/6 inhibitor (32), in MCF-7 Y537S cells (Figure 5, A–J).